Healthcare / Drug Manufacturers - Specialty & GenericUpdated 2026-05-10 22:07 UTC

COLL stock hub

Collegium Pharmaceutical, Inc. has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

COLLis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

1.2B

NASDAQ

Market data

Live price

Current market quote for this ticker.

Current price

COLL

In the news

Latest news · COLL

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/E5.1

P25 12.3P50 18.4P75 33.1

Trailing P/E23

P25 14.9P50 23.2P75 38.5

ROE27.4

P25 -105.6P50 -46.5P75 -3.1

ROIC16.8

P25 -63.1P50 -27.3P75 0.5

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All COLL market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

256

Groups with data

Currency

USD

Showing 256 of 256 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Cik	0001267565
Company name	Collegium Pharmaceutical, Inc.
Country	United States
Country code	US
Cusip	19459J104
Employees	423
Employees Change	66%
Employees Change Percent	18.49
Enterprise value	$1.7B
Exchange	NASDAQ
Financial currency	USD
First seen	2026-05-09
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	2015-05-07
Isin	US19459J1043
Last refreshed	2026-05-10
Market cap	$1.2B
Market cap category	Small-Cap
Price	$37.8
Price currency	USD
Rev Per Employee	1,882,576.83x
Sector	Healthcare
Sic	2834
Symbol	COLL
Website	https://www.collegiumpharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	6.11%
EV Earnings	23.13x
EV Sales Forward	2.05x
EV/EBIT	8.69x
EV/EBITDA	4.08x
EV/FCF	5.26x
EV/Sales	2.18x
FCF yield	26.9%
Forward P/E	5.1x
P/B ratio	3.92x
P/E ratio	23.05x
P/S ratio	1.54x
PE Ratio3 Y	23.85x
PE Ratio5 Y	20.13x
PS Forward	1.45x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT Margin	25.07%
EBITDA Margin	53.38%
FCF margin	41.42%
Gross margin	89.17%
Gross Profit	$710.1M
Gross Profit Growth	24.15%
Gross Profit Growth Q	10.52%
Gross Profit Growth3 Y	17.28%
Gross Profit Growth5 Y	22.04%
Net Income	$74.9M
Net Income Growth	70.75%
Net Income Growth Q	499.75%
Net Income Growth Quarters	3%
Net Income Growth Years	0%
Net Income Growth5 Y	12.3%
Pretax Margin	13.59%
Profit Margin	9.41%
Profit Per Employee	$177,184
Profitable Years	3
ROA	7.6
Roa5y	6.05
ROCE	16.4
ROE	27.41
Roe5y	21.04
ROIC	16.82
Roic5y	12.84

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr10y	9.61%
Cagr1y	39.77%
Cagr3y	18.16%
Cagr5y	10.45%
EPS Growth	58.63
EPS Growth Q	471.4
EPS Growth Quarters	3
EPS Growth Years	0
EPS Growth5 Y	11.06
FCF Growth	67.8%
FCF Growth Q	4.11%
FCF Growth3 Y	23.4%
FCF Growth5 Y	23.23%
OCF Growth	66.82%
OCF Growth Q	3.1%
OCF Growth3 Y	23.16%
OCF Growth5 Y	22.26%
Revenue Growth	19.88x
Revenue Growth Q	8.87x
Revenue Growth Quarters	16x
Revenue Growth Years	4x
Revenue Growth3 Y	14.9x
Revenue Growth5 Y	19.91x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	$0.49
Assets	$1.7B
Cash	$421.8M
Current Assets	$745.7M
Current Liabilities	$435M
Debt	$929.7M
Debt EBITDA	$2.15
Debt Equity	$2.98
Debt FCF	$2.82
Equity	$312.4M
Interest Coverage	2.58
Liabilities	$1.3B
Long Term Assets	$906.3M
Long Term Liabilities	$904.6M
Net Cash	$-507.9M
Net Cash By Market Cap	$-41.43
Net Debt EBITDA	$1.19
Net Debt Equity	$1.63
Net Debt FCF	$1.54
Tangible Book Value	$-447.5M
Tangible Book Value Per Share	$-13.81
WACC	7.27

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	1.71
Inventory Turnover	2.16
Net Working Capital	$-77M
Quick ratio	1.5
Working Capital	$310.7M
Working Capital Turnover	$4.53

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-8.45%
Dividend Yield	0%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y total return	150.33%
1Y total return	39.74%
200-day SMA	39.52
3Y total return	64.99%
50-day SMA	35.03
50-day SMA vs 200-day SMA	50under200
5Y total return	64.35%
All Time High	50.79
All Time High Change	-25.57%
All Time High Date	2025-12-29
All Time Low	7.37
All Time Low Change	412.89%
All Time Low Date	2017-05-09
ATR	1.6
Beta	0.76
Beta1y	1.16
Beta2y	0.39
Ch YTD	-18.36
High	40.5
High52	50.79
High52 Date	2025-12-29
High52ch	-25.57%
Low	37.61
Low52	26.81
Low52 Date	2025-05-08
Low52ch	40.99%
Ma50ch	7.91%
Price vs 200-day SMA	-4.35%
RSI	62.66
RSI Monthly	53.89
RSI Weekly	48.1
Sharpe ratio	0.95x
Sortino ratio	1.7
Total Return	-8.45%
Tr YTD	-18.36
Tr1m	15.39%
Tr1w	10.14%
Tr3m	-20.6%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Analyst Count	5
Analyst Count Top	2
Analyst Price Target Top	$46.5
Analyst Ratings	Strong Buy
Analyst Ratings Top	Buy
Earnings EPS Estimate	$1.46
Earnings EPS Estimate Growth	-2.01
Earnings Revenue Estimate	183,740,880x
Earnings Revenue Estimate Growth	3.37x
Operating Income	$199.6M
Operating Income Growth	18.72
Operating Income Growth Q	26.74
Operating Income Growth3 Y	14.72
Operating Income Growth5 Y	22.92
Operating margin	25.07
Price target	$51.4
Price Target Change	$35.98
Price Target Change Top	$23.02

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	32,035,098%
Float Percent	98.77%
Net Borrowing	-61,487,000
Shares Insiders	1.11%
Shares Institutions	115.89%
Shares Out	32,433,779
Shares Qo Q	-0.03%
Shares Yo Y	8.45%
Short Float	18.84%
Short Ratio	9.32
Short Shares	18.61

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	$288.6M
Average Volume	516,893.55x
Bv Per Share	9.64
CAPEX	$-1.2M
Ch10y	150.3
Ch1m	15.39
Ch1w	10.14
Ch1y	39.74
Ch3m	-20.6
Ch3y	64.99
Ch5y	64.35
Ch6m	-10.64
Change	-3.89%
Change From Open	-4.67
Close	39.33
Days Gap	0.81
Depreciation Amortization	225,446,000
Dollar Volume	26,383,681.8
Earnings Date	2026-05-07
Earnings Time	bmo
EBIT	$199.6M
EBITDA	$425.1M
EPS	$1.64
F Score	8
FCF	$329.8M
FCF EV Yield	19.02x
FCF Per Share	$10.17
Financing CF	-106,351,000
Fiscal Year End	December
Founded	2,002
Goodwill	145,925,000
Graham Number	18.86127
Graham Upside	-50.1
Income Tax	$33.3M
Investing CF	-52,225,000
Is Primary Listing	1
Is Spac	No
Last Earnings Date	2026-05-07
Last Report Date	2026-03-31
Last Split Type	Never
Last10k Filing Date	2026-02-26
Lynch Fair Value	$20.17
Lynch Upside	-46.64
Ma150	40.77
Ma150ch	-7.29%
Ma20	34.5
Ma20ch	9.57%
Net CF	172,462,000
Next Earnings Date	2026-08-06
Open	39.65
Optionable	Yes
P FCF Ratio	3.72
P OCF Ratio	3.7
Position In Range	6.57
Post Close	37.8
Postmarket Change Percent	-0.24
Postmarket Price	$37.71
Ppne	15,636,000
Price Date	2026-05-08
Price EBITDA	$2.88
Relative Volume	1.35x
Revenue	796,330,000x
SBC By Revenue	5.18x
Share Based Comp	41,262,000
Tax By Revenue	4.18x
Tax Rate	30.75%
Tr6m	-10.64%
Us State	Massachusetts
Volume	697,981
Z Score	1.56

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does COLL pay a dividend?

Capital-return profile for this ticker.

Performance

COLL stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns COLL?

Insider, institutional, and short-interest positioning.

Institutional ownership

+115.9%

Float: +98.8% of shares outstanding

Insider ownership

+1.1%

Stake held by company insiders. Higher generally signals alignment.

Negative means the company is buying back shares.

Technical

COLL momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

62.7

Neutral momentum band

Price vs 200-day MA

-4.3%

50/200-day relationship not available

Beta (5Y)

0.76

Less volatile than the market

Sharpe ratio

0.95

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About COLL

Hub-level FAQ points readers to the deeper analysis pages.

What is the current COLL stock rating?

Collegium Pharmaceutical, Inc. is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full COLL analysis?

The full report lives at /stocks/COLL/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for COLL?

The latest report frames COLL around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the COLL page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.